Gilead Sciences
Market Cap
US$82.6b
Last Updated
2019/10/21 23:36 UTC
Data Sources
Company Financials +
Executive Summary
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally.
Snowflake
Fundamentals
Good value with adequate balance sheet and pays a dividend.
Similar Companies
Share Price & News
How has Gilead Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.1%
GILD
2.0%
US Biotechs
1.0%
US Market
1 Year Return
-9.9%
GILD
-5.5%
US Biotechs
8.0%
US Market
Return vs Industry: GILD underperformed the US Biotechs industry which returned -5.5% over the past year.
Return vs Market: GILD underperformed the US Market which returned 8% over the past year.
Shareholder returns
| GILD | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.1% | 2.0% | 1.0% |
| 30 Day | -1.8% | -2.2% | -0.07% |
| 90 Day | -1.8% | -2.0% | -1.0% |
| 1 Year | -6.5%-9.9% | -4.6%-5.5% | 10.4%8.0% |
| 3 Year | -3.3%-12.1% | 15.4%11.4% | 46.2%36.7% |
| 5 Year | -34.5%-42.1% | -3.1%-7.8% | 64.3%46.2% |
Price Volatility Vs. Market
How volatile is Gilead Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
21 hours ago | Simply Wall St
Should You Buy Gilead Sciences, Inc. (NASDAQ:GILD) For Its Dividend?2 weeks ago | Simply Wall St
Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?1 month ago | Simply Wall St
Can Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Continue To Surpass The Industry Average?Valuation
Is Gilead Sciences undervalued compared to its fair value and its price relative to the market?
25.5%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GILD ($65.21) is trading below our estimate of fair value ($87.51)
Significantly Below Fair Value: GILD is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: GILD is good value based on its PE Ratio (14.1x) compared to the Biotechs industry average (16.4x).
PE vs Market: GILD is good value based on its PE Ratio (14.1x) compared to the US market (17.6x).
Price to Earnings Growth Ratio
PEG Ratio: GILD is good value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: GILD is overvalued based on its PB Ratio (3.7x) compared to the US Biotechs industry average (2.6x).
Next Steps
Future Growth
How is Gilead Sciences forecast to perform in the next 1 to 3 years based on estimates from 25 analysts?
14.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GILD's forecast earnings growth (14.2% per year) is above the savings rate (2.7%).
Earnings vs Market: GILD's earnings (14.2% per year) are forecast to grow slower than the US market (14.5% per year).
High Growth Earnings: GILD's earnings are forecast to grow, but not significantly.
Revenue vs Market: GILD's revenue (2% per year) is forecast to grow slower than the US market (7.2% per year).
High Growth Revenue: GILD's revenue (2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GILD's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Gilead Sciences performed over the past 5 years?
-20.4%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: GILD's earnings have declined by -20.4% per year over the past 5 years.
Accelerating Growth: GILD's earnings growth over the past year (169.7%) exceeds its 5-year average (-20.4% per year).
Earnings vs Industry: GILD earnings growth over the past year (169.7%) exceeded the Biotechs industry 83.4%.
Return on Equity
High ROE: Whilst GILD's Return on Equity (26.13%) is high, this metric is skewed due to their high level of debt.
Return on Assets
ROA vs Industry: GILD's Return on Assets is below or equal to the Biotechs industry average last year.
Return on Capital Employed
ROCE Improving: GILD's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Gilead Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: GILD's short term assets ($33.7B) exceeds its short term liabilities ($9.0B)
Long Term Liabilities: GILD's short term assets (33.7B) exceeds its long term liabilities (31.5B)
Debt to Equity History and Analysis
Debt Level: GILD's debt to equity ratio (114.6%) is considered high
Reducing Debt: GILD's debt to equity ratio has increased from 57.8% to 114.6% over the past 5 years.
Debt Coverage: GILD's debt is well covered by operating cash flow (31.5%).
Interest Coverage: GILD's interest payments on its debt are well covered by EBIT (9x coverage).
Balance Sheet
Inventory Level: GILD has a low level of unsold assets or inventory.
Debt Coverage by Assets: GILD's debt is covered by short term assets (assets are 1.293060x debt).
Next Steps
Dividend
What is Gilead Sciences's current dividend yield, its reliability and sustainability?
3.86%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: GILD's dividend (3.86%) is higher than the bottom 25% of dividend payers in the US market (1.44%).
High Dividend: GILD's dividend (3.86%) is in the top 25% of dividend payers in the US market (3.68%)
Stable Dividend: Whilst dividend payments have been stable, GILD has been paying a dividend for less than 10 years.
Growing Dividend: GILD's dividend payments have increased, but the company has only paid a dividend for 4 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (51.7%), GILD's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GILD's dividends in 3 years are forecast to be well covered by earnings (40.3% payout ratio).
Next Steps
Management
What is the CEO of Gilead Sciences's salary, the management and board of directors tenure and is there insider trading?
2.3yrs
Average management tenure
CEO
Dan O'Day (55yo)
0.6yrs
Tenure
Mr. Daniel O'Day, also known as Dan, has been the Chairman and Chief Executive Officer of Gilead Sciences, Inc. since March 01, 2019. Mr. O'Day was an Executive of Roche Holding AG since December 31, 2018 ...
Management Age and Tenure
2.3yrs
Average Tenure
55.5yo
Average Age
Experienced Management: GILD's management team is considered experienced (2.3 years average tenure).
Board Age and Tenure
6.4yrs
Average Tenure
72.5yo
Average Age
Experienced Board: GILD's board of directors are considered experienced (6.4 years average tenure).
Insider Trading
Insider Buying: GILD insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Legal Officer Executive VP of Corporate Affairs |
| Shares | 608 |
| Max Price | US$64.35 |
Ownership Breakdown
Management Team
Bill Lee (64yo)
Executive Vice President of Research
- Tenure: 18.9yrs
- Compensation: US$569.78k
Andrew Dickinson (49yo)
Executive Vice President of Corporate Development & Strategy
- Tenure: 1.3yrs
Robin Washington (56yo)
CFO & Executive VP
- Tenure: 11.4yrs
- Compensation: US$6.34m
Taiyin Yang (65yo)
Executive Vice President of Pharmaceutical Development & Manufacturing
- Tenure: 14.3yrs
Dan O'Day (55yo)
Chairman & CEO
- Tenure: 0.6yrs
Brett Pletcher (51yo)
Executive VP of Corporate Affairs
- Tenure: 4.3yrs
Johanna Mercier
Executive VP & Chief Commercial Officer
- Tenure: 0.3yrs
Sung Lee
VP of Investor Relations
- Tenure: 3.3yrs
Diana Brainard
Senior Vice President of HIV & Emerging Viral Infections
- Tenure: 1.2yrs
Jyoti Mehra
Executive Vice President of Human Resources
- Tenure: 0.2yrs
Board Members
Per Wold-Olsen (72yo)
Independent Director
- Tenure: 9.8yrs
- Compensation: US$449.96k
George Shultz (98yo)
Board Advisor & Director Emeritus
- Tenure: 0yrs
Paul Berg (92yo)
Member of Scientific Advisory Board
- Tenure: 0yrs
- Compensation: US$16.00k
Gayle Wilson (76yo)
Independent Director
- Tenure: 18yrs
- Compensation: US$429.96k
Eugene Schiff
Member of the Scientific Advisory Board
- Tenure: 0yrs
Rich Whitley (73yo)
Independent Director & Member of Independent Health Policy Advisory Board
- Tenure: 0yrs
- Compensation: US$429.96k
John Cogan (72yo)
Lead Independent Director
- Tenure: 6.4yrs
- Compensation: US$454.96k
Kelly Kramer (51yo)
Independent Director
- Tenure: 3.2yrs
- Compensation: US$417.87k
Dan O'Day (55yo)
Chairman & CEO
- Tenure: 0.6yrs
Joel Huff
Chairperson of Scientific Advisory Board
- Tenure: 0yrs
Company Information
Gilead Sciences, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Gilead Sciences, Inc.
- Ticker: GILD
- Exchange: NasdaqGS
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$82.586b
- Shares outstanding: 1.27b
- Website: https://www.gilead.com
Number of Employees
Location
- Gilead Sciences, Inc.
- 333 Lakeside Drive
- Foster City
- California
- 94404
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GILD | SWX (SIX Swiss Exchange) | Yes | Common Stock | CH | CHF | Jan 1992 |
| GILD | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jan 1992 |
| GILD * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Jan 1992 |
| GIS | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 1992 |
| GILD | SNSE (Santiago Stock Exchange) | Yes | Common Stock | CL | USD | Jan 1992 |
| GIS | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Jan 1992 |
| 0QYQ | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Jan 1992 |
| GILD | WBAG (Wiener Boerse AG) | Yes | Common Stock | AT | EUR | Jan 1992 |
| GILD | BIT (Borsa Italiana) | Yes | Common Stock | IT | EUR | Jan 1992 |
| GILD34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH REPR 1/2 COM USD0.001 | BR | BRL | Apr 2016 | |
| GILD | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH 4 REP 1 COM USD0.001 | AR | ARS | Apr 2019 |
Biography
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. T ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/21 23:36 |
| End of Day Share Price | 2019/10/21 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.